545 related articles for article (PubMed ID: 26671269)
1. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
Chahine EB; Sourial M; Ortiz R
Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269
[TBL] [Abstract][Full Text] [Related]
2. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
3. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
4. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
Mawal Y; Critchley IA; Riccobene TA; Talley AK
Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166
[TBL] [Abstract][Full Text] [Related]
5. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
Nicolau DP
Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
Falcone M; Paterson D
J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
[TBL] [Abstract][Full Text] [Related]
7. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
8. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.
Buckman SA; Krekel T; Muller AE; Mazuski JE
Expert Opin Pharmacother; 2016 Dec; 17(17):2341-2349. PubMed ID: 27758148
[TBL] [Abstract][Full Text] [Related]
9. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis.
Zhong H; Zhao XY; Zhang ZL; Gu ZC; Zhang C; Gao Y; Cui M
Int J Antimicrob Agents; 2018 Oct; 52(4):443-450. PubMed ID: 30012440
[TBL] [Abstract][Full Text] [Related]
11. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
12. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.
Qin X; Tran BG; Kim MJ; Wang L; Nguyen DA; Chen Q; Song J; Laud PJ; Stone GG; Chow JW
Int J Antimicrob Agents; 2017 May; 49(5):579-588. PubMed ID: 28363526
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
[TBL] [Abstract][Full Text] [Related]
14. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
Cheng K; Newell P; Chow JW; Broadhurst H; Wilson D; Yates K; Wardman A
Drug Saf; 2020 Aug; 43(8):751-766. PubMed ID: 32602065
[TBL] [Abstract][Full Text] [Related]
15. Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
Hidalgo JA; Vinluan CM; Antony N
Drug Des Devel Ther; 2016; 10():2379-86. PubMed ID: 27528799
[TBL] [Abstract][Full Text] [Related]
16. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
[TBL] [Abstract][Full Text] [Related]
17. Ceftazidime/Avibactam (Avycaz) -- a new intraveneous antibiotic.
Med Lett Drugs Ther; 2015 May; 57(1469):79-80. PubMed ID: 25989198
[No Abstract] [Full Text] [Related]
18. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.
Lucasti C; Popescu I; Ramesh MK; Lipka J; Sable C
J Antimicrob Chemother; 2013 May; 68(5):1183-92. PubMed ID: 23391714
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Mazuski JE; Gasink LB; Armstrong J; Broadhurst H; Stone GG; Rank D; Llorens L; Newell P; Pachl J
Clin Infect Dis; 2016 Jun; 62(11):1380-1389. PubMed ID: 26962078
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.
Alidjanov JF; Fritzenwanker M; Hoffman I; Wagenlehner FM
Future Microbiol; 2017 Jun; 12():655-670. PubMed ID: 28338347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
